Search results for "prostate"

showing 10 items of 621 documents

2021

Objective: Radical prostatectomy (RP) is a frequent treatment for men suffering from localized prostate cancer (PCa). Whilst offering a high chance for cure, it does not come without a significant impact on health-related quality of life. Herein we review the common adverse effects RP may have over the course of time.Methods: A collaborative narrative review was performed with the identification of the principal studies on the topic. The search was executed by a relevant term search on PubMed from 2010 to February 2021.Results: Rates of major complications in patients undergoing RP are generally low. The main adverse effects are erectile dysfunction varying from 11 to 87% and urinary incont…

medicine.medical_specialtyUrinary continencebusiness.industryProstatectomymedicine.medical_treatment030232 urology & nephrologyUrinary incontinencemedicine.disease03 medical and health sciencesProstate cancer0302 clinical medicineErectile dysfunctionQuality of life030220 oncology & carcinogenesismedicineSurgeryMajor complicationmedicine.symptomAdverse effectbusinessIntensive care medicineFrontiers in Surgery
researchProduct

Abstract 2141: Stromal SPARC deficiency skews prostate cancer toward neuroendocrine differentiation

2018

Abstract Tumor progression is a multifaceted process in which, complex interactions between tumor and different types of stromal cells and extracellular matrix components, actively contribute to its phenotypic heterogeneity. Among extracellular matrix proteins, secreted protein acidic and rich in cysteine (SPARC) has been deeply studied since conflicting reports have described its expression to be either increased or decreased in different cancer settings, also depending on whether it is produced by the neoplasm or by the neighboring stroma. Nevertheless, the different contribution of tumor- or stromal-derived SPARC in prostate tumor microenvironment has not been addressed at least for tumo…

Cancer ResearchTumor microenvironmentStromal cellCancerBiologymedicine.diseaseNeuroendocrine differentiationProstate cancerOncologyTumor progressionmedicineCancer researchAdenocarcinomaTrampCancer Research
researchProduct

Roles of p53, NF-κB and the androgen receptor in controlling NGAL expression in prostate cancer cell lines

2018

Neutrophil gelatinase-associated lipocalin (NGAL a.k.a lipocalin 2, lnc2) is a secreted protein which can form a complex with matrix metalloproteinase-9 (MMP9). This MMP9/NGAL complex has been associated with metastasis. MMP9 and NGAL are detected in the urine of patients afflicted with many different types of cancer, including prostate cancer. The effects of p53, NF-κB and the androgen receptor (AR) on the expression of NGAL was examined in four prostate cancer cell lines. Prostate cancer cell lines that are AR negative and expressed either mutant or no p53 (DU145 and PC3) displayed higher levels of NGAL expression compared to the prostate cancer cell lines (LNCaP and 22Rv-1) which are AR …

Male0301 basic medicinep53Cancer ResearchLipocalinMMP9Metastasis03 medical and health sciencesProstate cancerDU145GeneticCell Line Tumorandrogen receptorLNCaPGeneticsmedicineHumansNF-kappaBNGALMolecular BiologyChemistryNF-kappa BProstatic Neoplasmsmedicine.diseaseprostate cancerGene Expression Regulation NeoplasticAndrogen receptor030104 developmental biologyMatrix Metalloproteinase 9Receptors AndrogenCell cultureCancer researchMolecular MedicineTumor Suppressor Protein p53
researchProduct

Polymorphisms of an innate immune gene, toll-like receptor 4, and aggressive prostate cancer risk: a systematic review and meta-analysis.

2014

Background: Toll-like receptor 4 (TLR4) is one of the best known TLR members expressed on the surface of several leukocytes and tissue cells and has a key function in detecting pathogen and danger-associated molecular patterns. The role of TLR4 in the pathophysiology of several age-related diseases is also well recognized, such as prostate cancer (PCa). TLR4 polymorphisms have been related to PCa risk, but the relationship between TLR4 genotypes and aggressive PCa risk has not been evaluated by any systematic reviews. Methods: We performed a systematic review and meta-analysis of candidate-gene and genome-wide association studies analyzing this relationship and included only white populatio…

MaleProstate cancer polymorphisms of TLR4 aggressive prostate cancer risk meta-analysisSystematic Reviewslcsh:MedicineGenome-wide association studySingle-nucleotide polymorphismBiologyResearch and Analysis MethodsBioinformaticsPolymorphism Single NucleotideProstate cancerGenotypeGeneticsCancer GeneticsmedicineHumansSettore MED/05 - Patologia ClinicaGenetic Predisposition to DiseaseStatistical Methodslcsh:ScienceGenotypingGenetic associationEvolutionary BiologyMultidisciplinarylcsh:RProstatic NeoplasmsBiology and Life SciencesResearch Assessmentmedicine.diseaseImmunity InnateToll-Like Receptor 4Systematic reviewMeta-analysisPhysical SciencesGenetic Polymorphismlcsh:QPopulation GeneticsMathematicsStatistics (Mathematics)Genome-Wide Association StudyResearch ArticleMeta-AnalysisPLoS ONE
researchProduct

PSA and PSA Kinetics Thresholds for the Presence of 68Ga-PSMA-11 PET/CT-Detectable Lesions in Patients with Biochemical Recurrent Prostate Cancer

2020

68Ga-PSMA-11 positron-emission tomography/computed tomography (PET/CT) is commonly used for restaging recurrent prostate cancer (PC) in European clinical practice. The goal of this study is to determine the optimum time for performing these PET/CT scans in a large cohort of patients by identifying the prostate-specific-antigen (PSA) and PSA kinetics thresholds for detecting and localizing recurrent PC. This retrospective analysis includes 581 patients with biochemical recurrence (BC) by definition. The performance of 68Ga-PSMA-11 PET/CT in relation to the PSA value at the scan time as well as PSA kinetics was assessed by the receiver-operating-characteristic-curve (ROC) generated by plottin…

Biochemical recurrenceCancer Researchmedicine.medical_treatment68Gallium-PSMA PET/CTurologic and male genital diseaseslcsh:RC254-282030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancer0302 clinical medicine<sup>68</sup>gallium-psma pet/ctprostate-specific-antigenPSA kinetics thresholdsbiochemical recurrenceMedicineoptimal cutoff levelPET-CTPsa kineticsbusiness.industryProstatectomylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensprostate cancermedicine.diseaseRadiation therapyProstate-specific antigenOncology030220 oncology & carcinogenesisRecurrent prostate cancerbusinessNuclear medicineCancers
researchProduct

Resección extendida y exenteración pélvica en el cáncer de recto del tercio inferior

2014

Approximately 10% of all low rectal cancer needs surgical resection extended to other pelvic structures. Indication for extended resection should be given according to a precise systemic and local preoperative staging. Magnetic Resonance Imaging is the most important instrument utilized by the Multidisciplinary Team to decide therapeutic strategy according to the surgical risk. The status of the pathological circumferential resection margin is the most important prognostic factor determining local recurrence risk and oncological outcome and for this reason it should be considered pivotal in the decision of the strategy of treatment. When extended resection is performed, the presence of an e…

medicine.medical_specialtymedicine.diagnostic_testPelvic exenterationProstatectomybusiness.industryColorectal cancermedicine.medical_treatmentMagnetic resonance imagingSacrummedicine.diseaseSurgeryPlastic surgerymedicine.anatomical_structureProstatemedicineVaginaSurgerybusinessCirugía Española
researchProduct

MODULATION OF BLADDER α1-ADRENERGIC RECEPTOR SUBTYPE EXPRESSION BY BLADDER OUTLET OBSTRUCTION

2002

Purpose: α1-Adrenergic receptor (α1AR) antagonists are effective for relieving obstructive and irritative symptoms in patients with bladder outlet obstruction. While the α1aAR is responsible for prostate smooth muscle relaxation and outlet obstruction relief, to our knowledge the mechanisms underlying the relief of irritative symptoms remain to be determined. Therefore, we investigated mechanisms by which bladder α1AR subtypes may be involved in this process.Materials and Methods: We studied 42 rats, including 6 unoperated controls, 17 sham operated controls and 19 obstructed animals. Animals were characterized for baseline voiding pattern, followed by surgical intervention or sham surgery …

Detrusor musclemedicine.medical_specialtyUrinary bladderbusiness.industryUrologyUrinary bladder neck obstructionSham surgeryUrologyurologic and male genital diseasesmedicine.diseaseMuscle hypertrophySurgeryNeck of urinary bladderBladder outlet obstructionmedicine.anatomical_structureProstatemedicinebusinessJournal of Urology
researchProduct

PO-1046: Quantification of dosimetric uncertainty in patients treated with brachytherapy in localized prostate cancer

2015

Oncologymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentBrachytherapyHematologymedicine.diseaseProstate cancerOncologyRadiology Nuclear Medicine and imagingInternal medicinemedicineRadiology Nuclear Medicine and imagingIn patientRadiologybusinessRadiotherapy and Oncology
researchProduct

Regulation of cell-to-cell communication in non-tumorigenic and malignant human prostate epithelial cells.

2002

BACKGROUND Gap-junction-mediated intercellular communication (GJIC) is required for normal development and tissue homeostasis. However, the role of GJIC in human prostate carcinogenesis and progression remains ill-defined. METHODS The ability of hormones, anti-hormones, and the anti-hypertensive drug, forskolin, to restore GJIC in non-tumorigenic (RWPE-1 and PWR-1E) and malignant (RWPE-2, LNCaP, DU-145) human prostate epithelial cell lines, was examined by Scrape-Loading/Dye Transfer (SL/DT) and Fluorescence Recovery After Photobleaching (FRAP) methods using an Ultima laser cytometer. RESULTS Results from both assays show that PWR-1E, RWPE-2, LNCaP, and DU-145 cells have weak or absent GJIC…

Malemedicine.medical_specialtyEstroneUrologyCell CommunicationBiologyurologic and male genital diseasesmedicine.disease_causeConnexinschemistry.chemical_compoundProstate cancerCell–cell interactionInternal medicineLNCaPmedicineTumor Cells CulturedHumansTissue homeostasisForskolinColforsinGap JunctionsProstatic NeoplasmsEpithelial Cellsmedicine.diseaseEndocrinologyCell Transformation NeoplasticOncologychemistryCell cultureCancer researchCarcinogenesisImmortalised cell lineThe Prostate
researchProduct

Reply to: Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of ra…

2020

Oncologymedicine.medical_specialtylcsh:Diseases of the musculoskeletal systembusiness.industryMEDLINEEndocrine therapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaselcsh:RC254-282Bone healthlaw.inventionBreast cancermedicine.anatomical_structureDenosumabOncologyRandomized controlled triallawProstateMeta-analysisInternal medicineCommentarymedicinelcsh:RC925-935businessmedicine.drugJournal of Bone Oncology
researchProduct